ANTX
AN2 Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.37
−0.30%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$3.39
From 52W high−46.34%
Volume330870.00
Market cap$127.17M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$3.39
From 52W high
−46.34%
Volume
330870.00
Market cap
$127.17M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.3x
P/E (TTM)
—
RSI (14)
21.8
MomentumView details →
1D Return
−0.30%
YTD Return
+185.96%
SummaryUpdated Jun 1, 2026
AN2 Therapeutics, Inc. (NASDAQ:ANTX) is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in Menlo Park, California. The company went public in March 2022 and focuses on developing innovative treatments for rare, chronic, and serious infectious diseases. AN2 Therapeutics is currently advancing its lead drug candidate through clinical trials, representing a specialized approach to addressing unmet medical needs in the infectious disease space.
Similar companies
Latest newsMore news →
AN2 Therapeutics granted inducement equity awards to its newly-appointed Chief Medical Officer Cameron Trenor, consisting of a non-qualified stock option for 233,333 shares and restricted stock units representing 116,6 shares.33d agoAN2 Therapeutics appointed Cameron Trenor, M.D. as its new Chief Medical Officer.33d ago